<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p143" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_143{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_143{left:306px;bottom:30px;}
#t3_143{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_143{left:346px;bottom:30px;}
#t5_143{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_143{left:517px;bottom:30px;}
#t7_143{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_143{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_143{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_143{left:1124px;bottom:27px;letter-spacing:0.2px;}
#tb_143{left:35px;bottom:775px;letter-spacing:-0.35px;}
#tc_143{left:35px;bottom:746px;letter-spacing:0.08px;word-spacing:0.11px;}
#td_143{left:574px;bottom:754px;}
#te_143{left:583px;bottom:746px;}
#tf_143{left:35px;bottom:723px;letter-spacing:0.08px;word-spacing:0.11px;}
#tg_143{left:35px;bottom:700px;letter-spacing:0.02px;word-spacing:0.16px;}
#th_143{left:35px;bottom:677px;letter-spacing:-0.06px;word-spacing:0.24px;}
#ti_143{left:35px;bottom:654px;letter-spacing:0.07px;word-spacing:0.12px;}
#tj_143{left:35px;bottom:630px;letter-spacing:0.04px;word-spacing:-0.47px;}
#tk_143{left:35px;bottom:607px;letter-spacing:0.1px;word-spacing:0.09px;}
#tl_143{left:534px;bottom:615px;}
#tm_143{left:545px;bottom:607px;letter-spacing:-0.37px;}
#tn_143{left:35px;bottom:584px;letter-spacing:0.08px;word-spacing:0.11px;}
#to_143{left:35px;bottom:561px;letter-spacing:0.1px;word-spacing:-0.84px;}
#tp_143{left:251px;bottom:568px;}
#tq_143{left:260px;bottom:561px;letter-spacing:-0.05px;word-spacing:-0.74px;}
#tr_143{left:35px;bottom:537px;letter-spacing:0.13px;word-spacing:0.06px;}
#ts_143{left:35px;bottom:514px;letter-spacing:0.04px;word-spacing:0.14px;}
#tt_143{left:35px;bottom:491px;letter-spacing:0.04px;word-spacing:0.15px;}
#tu_143{left:35px;bottom:468px;letter-spacing:0.12px;word-spacing:-0.27px;}
#tv_143{left:35px;bottom:445px;letter-spacing:0.08px;word-spacing:0.11px;}
#tw_143{left:35px;bottom:421px;letter-spacing:0.11px;word-spacing:0.07px;}
#tx_143{left:35px;bottom:399px;letter-spacing:0.14px;word-spacing:0.04px;}
#ty_143{left:35px;bottom:359px;letter-spacing:0.05px;word-spacing:-0.2px;}
#tz_143{left:35px;bottom:336px;letter-spacing:0.04px;word-spacing:0.14px;}
#t10_143{left:35px;bottom:313px;letter-spacing:0.02px;word-spacing:-0.91px;}
#t11_143{left:35px;bottom:289px;letter-spacing:0.04px;word-spacing:-0.27px;}
#t12_143{left:35px;bottom:266px;letter-spacing:0.02px;word-spacing:0.16px;}
#t13_143{left:35px;bottom:243px;letter-spacing:0.07px;word-spacing:0.11px;}
#t14_143{left:35px;bottom:220px;letter-spacing:0.04px;word-spacing:0.15px;}
#t15_143{left:35px;bottom:196px;letter-spacing:0.04px;word-spacing:-1.09px;}
#t16_143{left:35px;bottom:173px;letter-spacing:0.07px;word-spacing:0.12px;}
#t17_143{left:35px;bottom:131px;letter-spacing:-0.22px;word-spacing:2.49px;}
#t18_143{left:35px;bottom:102px;letter-spacing:0.15px;word-spacing:0.04px;}
#t19_143{left:35px;bottom:79px;letter-spacing:-0.08px;word-spacing:0.27px;}
#t1a_143{left:240px;bottom:79px;letter-spacing:0.06px;}
#t1b_143{left:361px;bottom:79px;}
#t1c_143{left:618px;bottom:775px;letter-spacing:-0.24px;word-spacing:2.91px;}
#t1d_143{left:618px;bottom:755px;letter-spacing:-0.19px;}
#t1e_143{left:618px;bottom:727px;letter-spacing:0.18px;word-spacing:-1.23px;}
#t1f_143{left:944px;bottom:734px;}
#t1g_143{left:956px;bottom:727px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1h_143{left:618px;bottom:704px;letter-spacing:0.05px;word-spacing:-0.88px;}
#t1i_143{left:618px;bottom:680px;letter-spacing:0.11px;word-spacing:-0.88px;}
#t1j_143{left:618px;bottom:657px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1k_143{left:618px;bottom:634px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1l_143{left:618px;bottom:611px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1m_143{left:618px;bottom:588px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1n_143{left:618px;bottom:564px;letter-spacing:0.01px;word-spacing:-0.32px;}
#t1o_143{left:618px;bottom:541px;letter-spacing:-0.03px;word-spacing:0.37px;}
#t1p_143{left:618px;bottom:518px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1q_143{left:618px;bottom:495px;letter-spacing:0.11px;word-spacing:-0.29px;}
#t1r_143{left:618px;bottom:471px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1s_143{left:618px;bottom:431px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1t_143{left:618px;bottom:408px;letter-spacing:0.18px;word-spacing:-0.49px;}
#t1u_143{left:618px;bottom:385px;letter-spacing:-0.05px;word-spacing:0.23px;}
#t1v_143{left:618px;bottom:363px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1w_143{left:618px;bottom:339px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1x_143{left:618px;bottom:316px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1y_143{left:618px;bottom:293px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1z_143{left:618px;bottom:270px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t20_143{left:618px;bottom:247px;letter-spacing:0.11px;word-spacing:-0.95px;}
#t21_143{left:618px;bottom:223px;letter-spacing:0.17px;word-spacing:0.01px;}
#t22_143{left:618px;bottom:181px;letter-spacing:-0.15px;word-spacing:3.65px;}
#t23_143{left:618px;bottom:152px;letter-spacing:0.05px;word-spacing:0.14px;}
#t24_143{left:618px;bottom:129px;letter-spacing:0.14px;word-spacing:0.05px;}
#t25_143{left:618px;bottom:106px;word-spacing:-0.75px;}
#t26_143{left:618px;bottom:83px;letter-spacing:0.03px;word-spacing:0.16px;}
#t27_143{left:618px;bottom:60px;letter-spacing:0.11px;word-spacing:0.07px;}
#t28_143{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_143{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_143{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_143{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_143{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_143{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s5_143{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s6_143{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_143{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s8_143{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts143" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg143Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg143" style="-webkit-user-select: none;"><object width="1210" height="935" data="143/143.svg" type="image/svg+xml" id="pdf143" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_143" class="t s0_143">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_143" class="t s1_143">© </span>
<span id="t3_143" class="t s0_143">(NCCN </span>
<span id="t4_143" class="t s1_143">© </span>
<span id="t5_143" class="t s0_143">), All rights reserved. NCCN Guidelines </span>
<span id="t6_143" class="t s1_143">® </span>
<span id="t7_143" class="t s0_143">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_143" class="t s2_143">NCCN Guidelines Version 4.2024 </span>
<span id="t9_143" class="t s2_143">Head and Neck Cancers </span>
<span id="ta_143" class="t s3_143">MS-2 </span>
<span id="tb_143" class="t s4_143">Overview </span>
<span id="tc_143" class="t s5_143">The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines </span>
<span id="td_143" class="t s6_143">® </span>
<span id="te_143" class="t s5_143">) </span>
<span id="tf_143" class="t s5_143">for Head and Neck Cancers address tumors arising from the oral cavity </span>
<span id="tg_143" class="t s5_143">(including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult </span>
<span id="th_143" class="t s5_143">primary cancers, salivary gland cancers, and mucosal melanoma (MM) </span>
<span id="ti_143" class="t s5_143">are also addressed. In 2024, it is estimated that about 71,100 new cases </span>
<span id="tj_143" class="t s5_143">of oral cavity, pharyngeal, and laryngeal cancers will occur, which account </span>
<span id="tk_143" class="t s5_143">for approximately 3.6% of new cancer cases in the United States. </span>
<span id="tl_143" class="t s6_143">1 </span>
<span id="tm_143" class="t s5_143">An </span>
<span id="tn_143" class="t s5_143">estimated 16,110 deaths from head and neck (H&amp;N) cancers will occur </span>
<span id="to_143" class="t s5_143">during the same time period. </span>
<span id="tp_143" class="t s6_143">1 </span>
<span id="tq_143" class="t s5_143">Squamous cell carcinomas account for more </span>
<span id="tr_143" class="t s5_143">than 90% of these tumors. Tobacco and alcohol use disorders are the </span>
<span id="ts_143" class="t s5_143">most common etiologies for oral cavity, hypopharynx, larynx, and human </span>
<span id="tt_143" class="t s5_143">papillomavirus (HPV)-unrelated oropharynx cancers. Patients with H&amp;N </span>
<span id="tu_143" class="t s5_143">cancers due to tobacco and alcohol are at risk for harboring synchronous </span>
<span id="tv_143" class="t s5_143">primary tumors and developing second primary neoplasms of the H&amp;N, </span>
<span id="tw_143" class="t s5_143">lung, esophagus, bladder, and other potential sites that are exposed to </span>
<span id="tx_143" class="t s5_143">these carcinogens. </span>
<span id="ty_143" class="t s5_143">Stage at diagnosis predicts survival rates and guides care of patients with </span>
<span id="tz_143" class="t s5_143">H&amp;N cancers. In general, stage I or II disease defines a relatively small </span>
<span id="t10_143" class="t s5_143">primary tumor with no nodal involvement amongst HPV-unrelated cancers. </span>
<span id="t11_143" class="t s5_143">Stage III or IV HPV-unrelated cancers and stages I, II, and III HPV-related </span>
<span id="t12_143" class="t s5_143">cancers may include larger primary tumors, which may invade underlying </span>
<span id="t13_143" class="t s5_143">structures and/or spread to regional nodes. Distant metastases are less </span>
<span id="t14_143" class="t s5_143">common at presentation as compared to lung and esophagus cancers. </span>
<span id="t15_143" class="t s5_143">More advanced TNM (tumor, node, metastasis) stages are associated with </span>
<span id="t16_143" class="t s5_143">worse survival. </span>
<span id="t17_143" class="t s4_143">Guidelines Update Methodology </span>
<span id="t18_143" class="t s5_143">The complete details of the Development and Update of the NCCN </span>
<span id="t19_143" class="t s5_143">Guidelines are available at </span><span id="t1a_143" class="t s7_143">www.NCCN.org</span><span id="t1b_143" class="t s5_143">. </span>
<span id="t1c_143" class="t s4_143">Literature Search Criteria and Guidelines Update </span>
<span id="t1d_143" class="t s4_143">Methodology </span>
<span id="t1e_143" class="t s5_143">Prior to the update of the NCCN Guidelines </span>
<span id="t1f_143" class="t s6_143">® </span>
<span id="t1g_143" class="t s5_143">for Head and Neck Cancers, </span>
<span id="t1h_143" class="t s5_143">an electronic search of the PubMed database was performed to obtain key </span>
<span id="t1i_143" class="t s5_143">literature in H&amp;N cancers published since the previous Guidelines update, </span>
<span id="t1j_143" class="t s5_143">using the following search terms: (head and neck cancer) OR (head and </span>
<span id="t1k_143" class="t s5_143">neck squamous cell carcinoma) OR (lip cancer) OR (oral cavity cancer) </span>
<span id="t1l_143" class="t s5_143">OR (oropharynx cancer) OR (hypopharynx cancer) OR (nasopharynx </span>
<span id="t1m_143" class="t s5_143">cancer) OR (larynx cancer) OR (paranasal tumor) OR (ethmoid sinus </span>
<span id="t1n_143" class="t s5_143">tumor) OR (maxillary sinus tumor) OR (salivary gland tumor) OR (mucosal </span>
<span id="t1o_143" class="t s5_143">melanoma head) OR (mucosal melanoma neck) OR (recurrent metastatic </span>
<span id="t1p_143" class="t s5_143">head neck cancer). The PubMed database was chosen because it </span>
<span id="t1q_143" class="t s5_143">remains the most widely used resource for medical literature and indexes </span>
<span id="t1r_143" class="t s5_143">peer-reviewed biomedical literature. </span>
<span id="t1s_143" class="t s5_143">The search results were narrowed by selecting studies in humans </span>
<span id="t1t_143" class="t s5_143">published in English. Results were confined to the following article types: </span>
<span id="t1u_143" class="t s5_143">Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; </span>
<span id="t1v_143" class="t s5_143">Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic </span>
<span id="t1w_143" class="t s5_143">Reviews; and Validation Studies. The data from key PubMed articles as </span>
<span id="t1x_143" class="t s5_143">well as articles from additional sources deemed as relevant to these </span>
<span id="t1y_143" class="t s5_143">guidelines as discussed by the panel during the Guidelines update have </span>
<span id="t1z_143" class="t s5_143">been included in this version of the Discussion section. Recommendations </span>
<span id="t20_143" class="t s5_143">for which high-level evidence is lacking are based on the panel’s review of </span>
<span id="t21_143" class="t s5_143">lower-level evidence and expert opinion. </span>
<span id="t22_143" class="t s4_143">Sensitive/Inclusive Language Usage </span>
<span id="t23_143" class="t s5_143">NCCN Guidelines strive to use language that advances the goals of </span>
<span id="t24_143" class="t s5_143">equity, inclusion, and representation. NCCN Guidelines endeavor to use </span>
<span id="t25_143" class="t s5_143">language that is person-first; not stigmatizing; anti-racist, anti-classist, anti- </span>
<span id="t26_143" class="t s5_143">misogynist, anti-ageist, anti-ableist, and anti-weight-biased; and inclusive </span>
<span id="t27_143" class="t s5_143">of individuals of all sexual orientations and gender identities. NCCN </span>
<span id="t28_143" class="t s8_143">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
